Endocrine effects of long-term calcineurin inhibitor use in solid organ transplant recipients

The calcineurin inhibitors (CNIs) ciclosporin and tacrolimus are cornerstone immunosuppressants in solid organ transplantation, yet calcineurin blockade in endocrine tissues produces characteristic metabolic sequelae. This review synthesizes evidence on CNI-related disturbances in glucose and lipid metabolism, mineral balance, bone, and neuroendocrine axes.

Calcineurin inhibitors precipitate post-transplant diabetes mellitus by blunting β-cell insulin release and augmenting insulin resistance; tacrolimus is consistently more diabetogenic than ciclosporin. Weight gain and atherogenic dyslipidemia are common. Both agents accelerate trabecular bone loss via osteoclast activation, significantly increasing early fracture risk. Calcineurin blockade downregulates TRPM6/7 channels and aldosterone synthase, causing chronic hypomagnesemia, hyperkalemic type IV-like renal tubular acidosis, and fludrocortisone-responsive hypoaldosteronism. Adrenal insufficiency is uncommon but requires vigilance during acute illness or steroid withdrawal. Gonadal dysfunction is mild and reversible. Ciclosporin-associated hypertrichosis is well-established, and tacrolimus-induced alopecia was reported. Thyroid impact is negligible. Sleep disturbances can occur. A pragmatic monitoring algorithm integrating biochemical panels, bone densitometry, and stress-responsive adrenal testing enables early detection. Therapeutic strategies include magnesium repletion, early antiresorptive therapy, judicious CNI minimization, fludrocortisone for refractory hyperkalemia, and use of cardio-renal-protective antidiabetic agents.

Because CNI-related endocrine toxicities are common yet modifiable, routine multidisciplinary endocrinology involvement should be standard transplant care. Prospective registry studies should validate these algorithms and quantify long-term benefits for graft and patient survival.